The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > ARCHIVE
ARCHIVE
- Drug Price Adjustment Range Must Be Reviewed: JMA
March 5, 2001
- JPMA Inaugurates 'Council on Planning & Policy'
March 5, 2001
- SSP Completely Acquires Nutrichem of Germany
March 5, 2001
- Korosho Asks Makers to Report Errors in Standard Product Code
March 5, 2001
- Roche CEO Expects Leadership from Mr Ogawa
March 5, 2001
- Nippon Shinyaku to Terminate Development of NS-49
March 5, 2001
- JPMA Compiles Report on Globalization
March 5, 2001
- Nippon Shinyaku, SSP to Codevelop Synthetic Steroid
March 5, 2001
- Drug Wholesaler Tie-ups, M&As in 2000
March 5, 2001
- Only 70% of Hospitals Hire No. of Drs Required by Law
March 5, 2001
- SAS Institute to Start New Portal Service for R&D
March 5, 2001
- COX2 Inhibitor Expected to Prevent NSAID-induced Ulcers: Pharmacia Forum
March 5, 2001
- METI Report Calls For Free Competition for Medical, Nursing Care Services
February 26, 2001
- BUSINESS NEWS IN BRIEF -1-
February 26, 2001
- Elimination of NHI Price SystemShould Be Considered: Prof. Tokita
February 26, 2001
- REGULATORY NEWS IN BRIEF
February 26, 2001
- WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2001
- New Law Specific for Medical Devices Is Necessary: JFITMA President
February 26, 2001
- Kirin to Sponsor Genomic Medical Engineering Course at Tottori Univ.
February 26, 2001
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…